Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR.B7-H3 T cells in Recurrent Epithelial Ovarian Cancer
NCT04670068Phase 1Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Jan 2021
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of iC9-CAR.B7-H3 T cells in epithelial ovarian cancer (EOC), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoints: Number of Participants With Dose Limiting Toxicities Based on CTCAE at 10 weeks, Number of Participants With Dose Limiting Toxicities Based on Cytokine Release Syndrome at 10 weeks and 1 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
iC9-CAR.B7-H3 T cells
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT04670068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670068.